Continuing Querlo’s executive interview series, Francesco Rulli, Global CEO of Querlo, spoke with Gabriel Jipa, Director of Upjohn-Pfizer, about the challenges and opportunities in the post-covid era and the role of Artificial Intelligence in the future.
Upjohn is a pharmaceutical manufacturing firm launched by Pfizer, an American based multinational pharmaceutical corporation. Upjohn manufactures an extensive line of prescription drugs to treat conditions including arthritis, cancer, and heart disease. Today, the company servers over 100 markets and has a network of 9 dedicated manufacturing sites.
Rather than trying to anticipate what’s to come, Gabriel wants to focus on the changes in the market since covid began. This will allow companies such as Upjohn to take action sooner. He believes it is hard to predict any challenges or opportunities in the post-covid era with all the current uncertainty in our world.
Artificial Intelligence will provide many new opportunities for companies trying to make informed business decisions. One of the key components of its success is to ensure the data is available. If it is applied the right way, Artificial Intelligence will be a very useful tool in the future. The next step will be to help companies adapt to this increased usage of technology.
To hear more from Gabriel, you can connect with him through LinkedIn.